In Re Omega Healthcare Inv'rs, Inc. SEC. Litig.

968 F.3d 204
CourtCourt of Appeals for the Second Circuit
DecidedAugust 3, 2020
Docket19-1095
StatusPublished
Cited by60 cases

This text of 968 F.3d 204 (In Re Omega Healthcare Inv'rs, Inc. SEC. Litig.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Omega Healthcare Inv'rs, Inc. SEC. Litig., 968 F.3d 204 (2d Cir. 2020).

Opinion

19-1095 In re Omega Healthcare Inv’rs, Inc. Sec. Litig. UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT ______________

August Term 2019

(Argued: November 13, 2019 | Decided: August 3, 2020)

Docket No. 19-1095

ROYCE SETZER,

Lead Plaintiff-Appellant,

EARL HOLTZMAN,

Plaintiff-Appellant,

DROR GRONICH, Individually and on behalf of all others similarly situated,

Plaintiff,

STEVEN KLEIN, Individually and on behalf of all others similarly situated,

Consolidated Plaintiff,

v.

OMEGA HEALTHCARE INVESTORS, INC., C. TAYLOR PICKETT, ROBERT O. STEPHENSON, DANIEL J. BOOTH,

Defendants-Appellees. ______________

Before: LEVAL, WESLEY, and LIVINGSTON, Circuit Judges. 1 Plaintiffs-Appellants brought this putative class action against Omega Healthcare Investors, Inc., a publicly traded real estate investment trust that invests in healthcare facilities, and against Omega’s chief executives, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, 15 U.S.C. §§ 78j(b), 78t(a), and Rule 10b-5, 17 C.F.R. § 240.10b–5. Plaintiffs claim that Omega misled investors by failing to disclose a $15 million working capital loan it made to one of its major tenants, Orianna Health Systems. According to Plaintiffs, this omission hid from investors the true magnitude of Orianna’s solvency problems. The district court dismissed Plaintiffs’ claims for, among other reasons, insufficiently alleging scienter. Because we find that the complaint adequately alleges that Omega acted with the requisite scienter in failing to disclose the loan, we REVERSE and REMAND for proceedings consistent with this opinion. _________________

JACOB A. GOLDBERG, (David Dean, on the brief) The Rosen Law Firm, P.A., Jenkintown, PA, for Plaintiffs-Appellants.

ERIC RIEDER, (Heather S. Goldman, on the brief), Bryan Cave Leighton Paisner, LLP, New York, NY, for Defendants-Appellees. _________________

WESLEY, Circuit Judge:

Plaintiffs-Appellants, Royce Setzer, Earl Holtzman, Dror Gronich, and

Steven Klein, brought this putative class action against Omega Healthcare

Investors, Inc., a publicly traded Maryland corporation that invests in healthcare

facilities, and against Omega’s chief executives. Plaintiffs assert claims under

Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange

2 Act”), 15 U.S.C. §§ 78j(b), 78t(a), and Rule 10b–5, 17 C.F.R. § 240.10b–5, on behalf

of a putative class of investors who purchased or otherwise acquired Omega’s

securities between May 3, 2017 and October 31, 2017 (the “Class Period”).

Plaintiffs claim that Omega misled investors by failing to disclose a $15 million

working capital loan it made to one of its major tenants, Orianna Health Systems.

According to Plaintiffs, this omission hid from investors an accurate picture of

Orianna’s financial difficulties. The district court dismissed the complaint,

holding, inter alia, that although the non-disclosure of the loan amounted to a

material omission, Plaintiffs failed to plead a strong inference that Omega acted

with the requisite scienter.

Because we find that the complaint adequately alleges that Omega acted

with scienter in failing to disclose the loan, we reverse the district court’s decision

and remand for proceedings consistent with this opinion.

3 BACKGROUND

I. Facts 1

Omega is a self-administered real estate investment trust that invests in

healthcare facilities, such as skilled nursing and assisted living facilities. Omega

either owns the properties and leases them to the facility operators, or it provides

operators with mortgage financing. Omega reports its financial performance to

the market through its Funds from Operations (“FFO”) and Adjusted Funds from

Operations (“AFFO”) metrics. Thus, Omega’s FFO and AFFO primarily reflect

rents paid by its operators. 2

1Because we review de novo a dismissal pursuant to Federal Rule of Civil Procedure 12(b)(6), we largely take the facts from Plaintiffs’ complaint and assume them to be true. See Kalnit v. Eichler, 264 F.3d 131, 137–38 (2d Cir. 2001). 2 According to Omega’s 2017 10-K: NAREIT [National Association of Real Estate Investment Trusts] FFO is a non-GAAP financial measure. We use NAREIT FFO as one of several criteria to measure the operating performance of our business. We further believe that by excluding the effect of depreciation, amortization, impairment on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, NAREIT FFO can facilitate comparisons of operating performance between periods and between other REITs. J.A. 138. 4 At all relevant times, Defendant C. Taylor Pickett served as Omega’s chief

executive officer; Defendant Robert O. Stephenson served as the chief financial

officer; and Defendant Daniel J. Booth served as the chief operating officer

(together, with Omega, “Defendants”).

By late 2016 and early 2017, Omega’s second largest operator, Orianna, 3

began experiencing severe financial difficulties and became delinquent on its rent.

Orianna operated 59 skilled nursing facilities across the country, representing

seven percent of Omega’s investment portfolio at that time (roughly $619 million

in gross investment). In response to Orianna’s financial troubles, on May 2, 2017,

Omega provided a $15 million working capital loan to the company (the “Loan”). 4

A. First Quarter: January 1, 2017 through March 31, 2017

Two days after it made the Loan, Omega held a conference call with analysts

to discuss its results for the first quarter of 2017. On the call, Defendant Booth

described Orianna’s “performance pressure,” which he claimed was

3 Orianna is also identified in Omega’s public filings as “New ARK Investments, Inc.,” the name of its affiliate. 4 The parties sometimes refer to the Loan as an $18.8 million line of credit. That figure includes half of the accumulated interest on the Loan. The amount disbursed, however, was $15 million. 5 “exacerbated” by “complete replacement of senior management” in 2016. J.A. 25

¶ 35. Booth indicated that “[t]he new management team well known and

respected by Omega worked throughout 2016 to transform the culture of the

company, which included changing out many facility-level management teams.”

Id. Booth acknowledged that during this “transition period” Orianna’s

operational performance dipped below 1x EBITDAR 5 coverage for 2016. Id.

However, in an effort to help Orianna during the transition period, Omega had

“embarked on an effort to sell off [Orianna’s] northwest region, which consisted

of 7 facilities,” and that “3 facilities [had] already been sold.” Id. at 25–26 ¶ 35.

Defendant Pickett added that Orianna was rebranding, moving its corporate

headquarters, and making significant business changes in an attempt to recover. 6

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
968 F.3d 204, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-omega-healthcare-invrs-inc-sec-litig-ca2-2020.